Akrotome Imaging

Executive Summary

Akrotome Imaging is a preclinical-stage biotechnology company developing its proprietary FIRE (Fluorescent Image Resection Enhancement) platform, which uses quenched activity-based probes (qABPs) to selectively illuminate cancer tissue during surgery. By remaining dark in healthy tissue and fluorescing only upon contact with tumor-specific enzymes, the probes aim to provide surgeons with real-time, high-resolution visualization of tumor margins, potentially reducing recurrence rates and improving patient outcomes. Focused initially on solid tumors, the technology addresses a critical need in oncologic surgery where incomplete resection remains a challenge. Founded in 2020 and headquartered in San Francisco, the company is actively advancing its pipeline toward the clinic, leveraging a novel mechanism distinct from conventional fluorescence-guided surgery agents. While still in early development, Akrotome's approach has garnered attention for its potential to enhance surgical precision across multiple cancer types. The company has not disclosed funding amounts or valuation, indicating a likely pre-seed or seed stage. Key near-term milestones include further preclinical validation, lead candidate selection for an Investigational New Drug (IND)-enabling study, and potential initiation of first-in-human trials. The success of the platform hinges on demonstrating target specificity, safety, and manufacturability, with the first clinical data expected to be a major inflection point. Given the competitive landscape of intraoperative imaging, Akrotome's differentiated mechanism could position it favorably if initial results are promising.

Upcoming Catalysts (preview)

• Q4 2026Preclinical proof-of-concept data in additional tumor models70% success
• Q2 2027IND filing for lead candidate45% success
• Q4 2027First-in-human trial initiation30% success